Olmutinib Induced Lichen Planus Like Eruption

被引:1
作者
Oh, Seung Hwan [1 ]
Byun, Hyun Jeong [1 ]
Oh, Se Jin [1 ]
Jun, Ji-Young [1 ]
Park, Ji-Hye [1 ]
Lee, Jong Hee [1 ]
Lee, Dong-Youn [1 ]
Lee, Joo-Heung [1 ]
Yang, Jun-Mo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Dermatol, 81 Irwon Ro, Seoul 06351, South Korea
关键词
Drug eruptions; EGFR tyrosine kinase inhibitor; Lichen planus; Olmutinib; TYROSINE KINASE INHIBITORS;
D O I
10.5021/ad.2018.30.4.451
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Drug induced lichen planus like eruption is an uncommon cutaneous adverse effect of several drugs. This appears symmetric eruption of erythematous or violaceous plaques resembling lichen planus on the trunk and extremities. A 50-year-old male presented with scaly, violaceous plaques and dusky brown macules on whole body. For four months, the patient was treated with olmutinib, an oral, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor. In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. The biopsy specimen from the patient showed features of lichen planus. We diagnosed him with olmutinib-induced lichen planus like eruption. He was treated with oral methylprednisolone and topical desoxymethasone 0.25% ointment. At the same time, olmutinib dose was decreased to three-fourths of this patient's starting dose. After that, the cutaneous lesions improved.
引用
收藏
页码:451 / 453
页数:3
相关论文
共 10 条
[1]   Dermatologic side effects associated with the epidermal growth factor receptor inhibitors [J].
Agero, Anna Liza C. ;
Dusza, Stephen W. ;
Benvenuto-Andrade, Cristiane ;
Busam, Klaus J. ;
Myskowski, Patricia ;
Halpern, Allan C. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :657-670
[2]  
Brauer Jeremy, 2009, Dermatol Online J, V15, P13
[3]   Drug-induced lichen planus [J].
Ellgehausen, P ;
Elsner, P ;
Burg, G .
CLINICS IN DERMATOLOGY, 1998, 16 (03) :325-332
[4]  
Goldsmith LA, 2012, FITZPATRICKS DERMATO, P304
[5]   Olmutinib: First Global Approval [J].
Kim, Esther S. .
DRUGS, 2016, 76 (11) :1153-1157
[6]  
Lacouture ME, 2013, EXPERT REV ANTICANC, V13, P721, DOI [10.1586/era.13.30, 10.1586/ERA.13.30]
[7]   Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor [J].
Lee, Kwang-Ok ;
Cha, Mi Young ;
Kim, Mira ;
Song, Ji Yeon ;
Lee, Jae-Ho ;
Kim, Young Hoon ;
Lee, Young-Mi ;
Suh, Kwee Hyun ;
Son, Jeewoong .
CANCER RESEARCH, 2014, 74 (19)
[8]   Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors [J].
Liao, Bin-Chi ;
Lin, Chia-Chi ;
Lee, Jih-Hsiang ;
Yang, James Chih-Hsin .
JOURNAL OF BIOMEDICAL SCIENCE, 2016, 23
[9]   Unique Cutaneous Reaction to Second-and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia [J].
Patel, Anisha B. ;
Solomon, Alvin R. ;
Mauro, Michael J. ;
Ehst, Benjamin D. .
DERMATOLOGY, 2016, 232 (01) :122-125
[10]   Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor [J].
Pretel-Irazabal, M. ;
Tuneu-Valls, A. ;
Ormaechea-Perez, N. .
ACTAS DERMO-SIFILIOGRAFICAS, 2014, 105 (07) :655-662